We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 12, 2020

FOLFIRI Plus Cetuximab or Bevacizumab for Advanced Colorectal Cancer

British Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

British Journal of Cancer
FOLFIRI Plus Cetuximab or Bevacizumab for Advanced Colorectal Cancer: Final Survival and Per-Protocol Analysis of FIRE-3, A Randomised Clinical Trial
Br. J. Cancer 2020 Nov 06;[EPub Ahead of Print], V Heinemann, LF von Weikersthal, T Decker, A Kiani, F Kaiser, SE Al-Batran, T Heintges, C Lerchenmüller, C Kahl, G Seipelt, F Kullmann, M Moehler, W Scheithauer, S Held, L Miller-Phillips, DP Modest, A Jung, T Kirchner, S Stintzing

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading